206 related articles for article (PubMed ID: 18434690)
1. Sustained remission after rituximab-containing chemotherapy for intravascular large B-cell lymphoma.
Shimada K; Kosugi H; Narimatsu H; Shimada S; Suzuki T; Ito M; Kinoshita T; Mori N; Naoe T
J Clin Exp Hematop; 2008 Apr; 48(1):25-8. PubMed ID: 18434690
[TBL] [Abstract][Full Text] [Related]
2. Brief-duration rituximab/chemotherapy followed by maintenance rituximab in patients with diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy: a phase II trial of the Sarah Cannon Oncology Research Consortium.
Hainsworth JD; Flinn IW; Spigel DR; Clark BL; Griner PL; Vazquez ER; Doss HH; Shipley D; Franco LA; Burris HA; Greco FA;
Clin Lymphoma Myeloma Leuk; 2010 Feb; 10(1):44-50. PubMed ID: 20223728
[TBL] [Abstract][Full Text] [Related]
3. [Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].
Wu HJ; Zhang QY; Chen DF; Guan XJ; Zhang BL; Ma J
Ai Zheng; 2005 Dec; 24(12):1498-502. PubMed ID: 16351800
[TBL] [Abstract][Full Text] [Related]
4. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
[TBL] [Abstract][Full Text] [Related]
5. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study.
Zinzani PL; Stefoni V; Finolezzi E; Brusamolino E; Cabras MG; Chiappella A; Salvi F; Rossi A; Broccoli A; Martelli M
Clin Lymphoma Myeloma; 2009 Oct; 9(5):381-5. PubMed ID: 19858058
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment of primary cardiac lymphoma by rituximab-CHOP and high-dose chemotherapy with autologous peripheral blood stem cell transplantation.
Nonami A; Takenaka K; Kamezaki K; Miyamoto T; Harada N; Nagafuji K; Teshima T; Harada M
Int J Hematol; 2007 Apr; 85(3):264-6. PubMed ID: 17483065
[TBL] [Abstract][Full Text] [Related]
7. [The efficacy and adverse effects of rituximab with CHOP or THP-COP in old-old and extremely old patients with diffuse large B cell lymphoma].
Kikukawa M; Miyazaki K; Kiuchi A; Abe S; Fujii H; Kanaya K; Shin K; Iwamoto T
Nihon Ronen Igakkai Zasshi; 2006 Mar; 43(2):236-40. PubMed ID: 16683659
[TBL] [Abstract][Full Text] [Related]
8. Aspects of chemotherapy schedules in young and elderly patients with aggressive lymphoma.
Zwick C; Gleissner B; Pfreundschuh M
Clin Lymphoma Myeloma; 2007 Dec; 8 Suppl 2():S43-9. PubMed ID: 18284715
[TBL] [Abstract][Full Text] [Related]
9. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
Récher C; Coiffier B; Haioun C; Molina TJ; Fermé C; Casasnovas O; Thiéblemont C; Bosly A; Laurent G; Morschhauser F; Ghesquières H; Jardin F; Bologna S; Fruchart C; Corront B; Gabarre J; Bonnet C; Janvier M; Canioni D; Jais JP; Salles G; Tilly H;
Lancet; 2011 Nov; 378(9806):1858-67. PubMed ID: 22118442
[TBL] [Abstract][Full Text] [Related]
10. Aggressive lymphoma: improving treatment outcome with rituximab.
Coiffier B; Pfreundschuh M; Stahel R; Vose J; Zinzani PL
Anticancer Drugs; 2002 Nov; 13 Suppl 2():S43-50. PubMed ID: 12710590
[TBL] [Abstract][Full Text] [Related]
11. Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi.
Merli F; Luminari S; Rossi G; Mammi C; Marcheselli L; Tucci A; Ilariucci F; Chiappella A; Musso M; Di Rocco A; Stelitano C; Alvarez I; Baldini L; Mazza P; Salvi F; Arcari A; Fragasso A; Gobbi PG; Liberati AM; Federico M
Leuk Lymphoma; 2012 Apr; 53(4):581-8. PubMed ID: 21895543
[TBL] [Abstract][Full Text] [Related]
12. Intravascular large B-Cell lymphoma with bone marrow involvement and superior sagittal sinus thrombosis: report of a case successfully treated with a CHOP/rituximab combination regimen.
Jardin F; Callonnec F; Contentin N; Picquenot JM; Gueit I; Héron F; Bastard C; Tilly H
Clin Lymphoma; 2005 Jun; 6(1):46-9. PubMed ID: 15989707
[TBL] [Abstract][Full Text] [Related]
13. Rituximab in the treatment of diffuse large B-cell lymphomas.
Coiffier B
Semin Oncol; 2002 Feb; 29(1 Suppl 2):30-5. PubMed ID: 11842386
[TBL] [Abstract][Full Text] [Related]
14. [Primary hepatic lymphoma - favorable outcome with chemotherapy plus rituximab].
Serrano-Navarro I; Rodríguez-López JF; Navas-Espejo R; Pérez-Jacoiste MA; Martínez-González MA; Grande C; Prieto S
Rev Esp Enferm Dig; 2008 Nov; 100(11):724-8. PubMed ID: 19159179
[TBL] [Abstract][Full Text] [Related]
15. Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma.
Coiffier B
Semin Oncol; 2002 Apr; 29(2 Suppl 6):18-22. PubMed ID: 12040530
[TBL] [Abstract][Full Text] [Related]
16. [Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China--a multi-center randomized trail].
Lin TY; Zhang HY; Huang Y; Guan ZZ; Shen T; Shi YK; Zhu J; Ke XY; Wang HQ; Shen ZX; Yu SY; Liu T; Shi XL
Ai Zheng; 2005 Dec; 24(12):1421-6. PubMed ID: 16351785
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of rituximab and reduced-dose cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy for elderly patient with diffuse large B-cell lymphoma.
Kayamori K; Shono K; Onoda M; Yokota A
Hematology; 2019 Dec; 24(1):52-59. PubMed ID: 30101679
[TBL] [Abstract][Full Text] [Related]
18. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
[TBL] [Abstract][Full Text] [Related]
19. Modified chop-chemotherapy plus rituximab for diffuse large b-cell lymphoma complicating ataxia-telangiectasia.
Rossi G; Zecca M; Marchi A; de Stefano P; Sammarchi L; Locatelli F
Br J Haematol; 2003 Jan; 120(2):369-71. PubMed ID: 12542504
[No Abstract] [Full Text] [Related]
20. Complete Remission and Long-term Survival of a Patient with a Diffuse Large B-cell Lymphoma Under
Gutsch J; Werthmann PG; Rosenwald A; Kienle GS
Anticancer Res; 2018 Sep; 38(9):5363-5369. PubMed ID: 30194190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
